This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Tolperisone

Katama Pharmaceuticals

Drug Names(s): Tolperisone, Viveo, AV650

Description: AV650 is an oral, centrally acting muscle relaxant. Its precise mechanism is not completely understood, though it blocks sodium and calcium channels. It possesses a high affinity for nervous system tissue, reaching highest concentrations in brain stem, spinal cord and peripheral nerves. Based on existing clinical data, AV650 is not sedating and does not interact with alcohol.

The active ingredient has been marketed in Eastern Europe, Asia and Germany for the treatment of muscular spasm and spasticity. Viveo is the 150 mg, branded tablet sold by Sanochemia and Orion in Europe (recommended dose range 300–450mg per day).

Deal Structure: Sanochemia and Avigen
In January 2006, Avigen signed a license and supply agreement for AV650 with a subsidiary of Sanochemia Pharmazeutika AG. Avigen will develop AV650 for the North American market; along with milestone payments, Avigen will pay royalty payments on sales.

Sanochemia and Orion
On January 19, 2006, Orion Corporation and Sanochemia signed an exclusive agreementon the marketing and distribution of tolperisone in Germany, Switzerland, Scandinavia and the Baltic States.

Sanochemia and Avigen
In November 2008, Avigen announced that the Company's contract with Sanochemia Pharmaceutica AG regarding AV650 has been terminated.

Sanochemia and Katama
In October 2012, Katama announced the signing of an exclusive license agreement with Sanochemia. The agreement provides Katama the exclusive right to develop and market Sanochemia's proprietary tolperisone formulation in North America. Katama will initially develop...See full deal structure in Biomedtracker

Partners: Sanochemia Pharmazeutika AG


Tolperisone News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug